NovaGene Therapeutics
Dana Whitfield · VP Regulatory Affairs KB v1Deal stage
— where this deal is in its journey, first contact to closeDeal snapshot
Win chance, the value at stake, and how far this deal has come.
Win chance
Weighted to $135K
Value at stake
Full value vs. risk-adjusted.
Pipeline progress
Qualified · 19d since touch
NovaGene Therapeutics is cooling in Qualified — 19 days since the last touch, $270K at risk. Recommended next move: Re-engage NovaGene Therapeutics.
Recommended: Re-engage NovaGene Therapeutics
A quick read on this deal from your agent — where it stands and the smartest next move — so you're prepared before you call or email. The agent never reaches out on its own.
Deal value
$270K
The full amount if it closes.
Weighted
$135K
50% chance of closing
Owner
Suren DheenWho's running this deal — that's you.
Last activity
Your most recent logged call, email, or note — 19 days ago.
Next step scheduled: Jul 27, 2026
Agent — next best action for this deal
Re-engage NovaGene Therapeutics
No activity in 19 days on a $270K deal sitting at "Qualified" — it's going cold. Draft a value nudge to bring it back.
Follow up with NovaGene Therapeutics
You set a follow-up with NovaGene Therapeutics for 7/27/2026. Draft the recap with a concrete next step so it doesn't slip.
Recommended Services
Position Clinical Trial Regulatory Support against NovaGene Therapeutics's near-term regulatory milestones.
Single-pane monitoring across FDA, EMA and 120+ agencies.
Activity
- InterestedJul 3, 2026 • 1:49 PM
Wants IND-to-BLA roadmap.
Follow-up Jul 27, 2026Logged by Suren Dheen